Purpose of review
To summarize all available data on targeting angiotensinogen
with RNA-based therapeutics as a new tool to combat cardiovascular diseases.
Liver-targeted, stable antisense oligonucleotides
and small interfering RNA targeting angiotensinogen
are now available, and may allow treatment with at most a few injections per year, thereby improving adherence. Promising results have been obtained in hypertensive animal models, as well as in rodent models of atherosclerosis, polycystic kidney disease and pulmonary fibrosis. The next step will be to evaluate the optimal degree of suppression, synergy with existing renin
–aldosterone system blockers, and to determine harmful effects of suppressing angiotensinogen
in the context of common comorbidities, such as heart failure and chronic kidney disease.
with RNA-based therapeutics is a promising new tool to treat hypertension and diseases beyond. Their long-lasting effects are particularly exciting, and if translated to a clinical application of at most a few administrations per year, may help to eliminate nonadherence.